At DeRoyal, we combine fundamental manufacturing capabilities with unique services and information technology tools to deliver unparalleled quality and value to our customers. Nearly 100 patents and 25,000 different products offered stand as testimony to the creative resolve of the DeRoyal team to deliver revolutionary products and services that benefit clinicians and patients.”
Clonallon are proud to be exclusive distributors of DeRoyal products for the UK and Ireland.
A-View®, A Step Forward Within the Medical Industry.
Clonallon are proud to announce that we will be distributing a new innovative product, A-View®, across the UK and Ireland, brought to the market by our partners, DeRoyal.
For more information about A-View®, please contact a member of our sales team: sales@clonallon.com
Click Image to Download The DeRoyal Surgical Accessories Catalogue.
Click Image to Download The DeRoyal Temperature Monitoring Catalogue.
An overview of A-View®
Helping to resolve the ‘blind spot’ of Transesophageal Echocardiograms.
One of the drawbacks of Transoesophageal (Oesophageal) Echocardiography (TEE) or (TOE) is that virtually all the distal ascending aorta (DAA) and aortic arch is ‘blind’ to this method as a result of the interposition of the air-filled trachea. This means that we have no real valuable information with respect to the level of atherosclerosis in this area.
A-View® Endotracheal Balloon Catheter is used to overcome the limitation of the so called ‘blind spot’ of TEE. After introduction of the saline filled catheter in the trachea, echo conduction through the trachea is enabled and the ascending aorta, aortic arch and its branching vessels can be imaged.
An informative video of A-View is available to view below.
Key Benefits of A-View®.
The use of A-View® in a large observational study has demonstrated a > 30% mortality reduction in patients in which A-View® was used1.
34% of the global total healthcare expenditure is spent on treating stroke patients 2. The routine use of A-View® prevents one in every 47 patients from developing a stroke3 and this produces a saving of €3,030 per patient.4
A-View® was used in 1,391 procedures. 12% of patients had to have their surgical approach modified following its use as outlined below.
The average healthcare cost of stroke per person, including in patient care, rehabilitation, follow-up care, is estimated at USD 140,048 in the United States 4.
The largest cost component of stroke was direct medical costs and indirect medical costs, accounting for 86.2% and 1.8% of the total cost respectively 4.
1 Klomp, J., 2017. Impact of Modified Transoesophageal Echocardiography on Mortality and Stroke after Cardiac Surgery: A Large Cohort Study. International Journal of Vascular Medicine,
2 Katan, M. and Luft, A., 2018. Global Health Neurology. Seminal Neurology, 38, pp.208-211.
3 Koffijerg, H., 2013. biomedcentral.com.
4 Robinson, J., Fox, K., Bullano, M. and Grandy, S., 2009. Atherosclerosis profile and incidence of cardiovascular events: a population-based survey. BMC Cardiovascular Disorders, 9(1).
Clinical and Business Case for A-View®
Clonallon’s Managing Director, Dermot Dempster, has put together a Clinical and Business Case for A-View®, which is available to view below.
For more information about A-View® download the guide below.